Cheap But High Purity; High Quality; 17A-Hydroxyprogesterone Caproate; Producer in China; 630-56-8

Synonyms: PREGN-4-ENE-3,20-DIONE HEXANOATE;17-((1-oxohexyl)oxy)-pregn-4-ene-20-dione;17-((1-Oxohexyl)oxy)pregn-4-ene-3,20-dione;17a-hydroxyprogesteronehexanoate;17-alpha-Hexanoyloxypregn-4-ene-3,20-dione;17alpha-Hydroxyprogesterone n-caproate;17-alpha-hydroxyprogesteronen-caproate;17-Hydroxypregn-4-ene-3,20-dione caproate 

CAS: 630-56-8 

MF: C27H40O4 

Hydroxyprogesterone caproate (OHPC) (INN, USAN, JAN) (brand names Delalutin, Proluton, Makena, Prodrox, Hylutin, many others), also known as hydroxyprogesterone hexanoate (BANM), is a steroidal progestin and derivative of 17α-hydroxyprogesterone (17α-OHP) that is related to other 17α-OHP derivatives such as chlormadinone acetate, cyproterone acetate, medroxyprogesterone acetate, and megestrol acetate. It is an ester of 17α-OHP formed from caproic acid (hexanoic acid).

OHPC was previously marketed under the trade name Delalutin by Squibb, which was approved by the United States (U.S.) Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999. It is also sold as Proluton throughout Europe. The U.S. FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy.